View Item 

Show simple item record

Challenges in Developing Evidence‐Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapy
dc.contributor.authorMueller, BAen_US
dc.contributor.authorSmoyer, WEen_US
dc.date.accessioned2015-01-07T15:24:37Z
dc.date.available2015-01-07T15:24:37Z
dc.date.issued2009-11en_US
dc.identifier.citationMueller, BA; Smoyer, WE (2009). "Challenges in Developing Evidence‐Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapy." Clinical Pharmacology & Therapeutics 86(5): 479-482.en_US
dc.identifier.issn0009-9236en_US
dc.identifier.issn1532-6535en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110047
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherHospiraen_US
dc.titleChallenges in Developing Evidence‐Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110047/1/cptclpt2009150.pdf
dc.identifier.doi10.1038/clpt.2009.150en_US
dc.identifier.sourceClinical Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceRonco, C. et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356, 26 – 30 ( 2000 ).en_US
dc.identifier.citedreferenceChurchwell, M.D., Pasko, D.A., Btaiche, I.F., Jain, J.C. & Mueller, B.A. Trace element removal during in vitro and in vivo continuous haemodialysis. Nephrol. Dial. Transplant. 22, 2970 – 2977 ( 2007 ).en_US
dc.identifier.citedreferenceManley, H.J., Cannella, C.A., Bailie, G.R. & St Peter, W.L. Medication‐related problems in ambulatory hemodialysis patients: a pooled analysis. Am. J. Kidney Dis. 46, 669 – 680 ( 2005 ).en_US
dc.identifier.citedreferenceUS Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis and Impact on Dosing and Labeling < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf > (14 May 1998).en_US
dc.identifier.citedreferenceVancomycin hydrochloride (vancomycin hydrochloride for injection) [package insert]. Lake Forest, IL: Hospira, 2004.en_US
dc.identifier.citedreferenceAronoff, G.R. et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children ( Philadelphia, PA: American College of Physicians, 2007 ).en_US
dc.identifier.citedreferenceUS Food and Drug Administration. Preliminary Concept Paper: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis and Impact on Dosing and Labeling < http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4351b1‐01‐FDA.pdf > (19 March 2008).en_US
dc.identifier.citedreferenceNational Kidney Foundation–Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am. J. Kidney Dis. 48 ( suppl. 1 ), S2 – S90 ( 2006 ).en_US
dc.identifier.citedreferenceStevenson, J.M. et al. Ertapenem clearance during modeled continuous renal replacement therapy. Int. J. Artif. Organs 31, 1027 – 1034 ( 2008 ).en_US
dc.identifier.citedreferenceTeraoka, T. et al. Prediction of iopromide reduction rates during haemodialysis using an in vitro dialysis system. Nephrol. Dial. Transplant. 20, 754 – 759 ( 2005 ).en_US
dc.identifier.citedreferencePalevsky, P.M., et al. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359, 7 – 20 ( 2008 ).en_US
dc.identifier.citedreferenceManley, H.J. et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not‐for‐profit dialysis provider. Nephrol. Dial. Transplant. 19, 1842 – 1848 ( 2004 ).en_US
dc.identifier.citedreferenceDreisbach, A.W. & Lertora, J.J. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. Drug Metab. Toxicol. 4, 1065 – 1074 ( 2008 ).en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cptclpt2009150.pdf
Size:
123.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.